Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
Stopped early · Phase 1/Phase 2
Conditions studied: Colorectal Cancer, Solid Tumors
In brief
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of revumenib in participants with colorectal cancer (CRC) or other solid tumors who have failed at least 1 prior line of therapy.
Key facts
- Study ID
- NCT05731947
- Run by
- Syndax Pharmaceuticals
- People needed
- 41
- Starts
- 2023-04-04
- Expected to finish
- 2025-06-30
- Last updated by the study team
- 2026-07-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Honor Health Research Institute — Scottsdale, Arizona, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center — Manhattan, New York, United States
- Gabrail Cancer Center — Canton, Ohio, United States
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States
- Inova Schar Cancer Institute — Fairfax, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.